English

THOST Projektmanagement GmbH
Villinger Straße 6 | D-75179 Pforzheim
+49 7231 1560-0
info@thost.de

Quality assurance is top priority

In pharmaceutical production quality assurance plays a fundamental role, because fluctuating quality can have a direct impact on the health of the consumer. A quality management system that complies with good management practice (GMP) ensures product quality and meets mandatory health authority requirements. Furthermore, pharmaceutical manufacturing approval processes require flawless documentation. Experts are required here – our employees. They know the processes in detail and thanks to their professional project management; they supervise plant construction in detail – from planning to the start of production.

Sector expertise

Selected references

provide exemplary insights into the diversity of projects as parts of a broad spectrum of experience. Further references on request under info@thost.de.

Pharmaceutical production facility
Expansion of a pharmaceutical production facility with  the construction of a new clinical sample production area for highly potent source materials in an existing building.
Production facility Darmstadt

Conversion of an existing chemical facility into a sealed production line (dust, liquids, steam) during operation, the integration of new apparatus and capacity expansion of reactor plant units.

Turnaround vitamin production, Grenzach-Wyhlen

These products are produced in the world’s biggest facility of its type. Modern process control systems run the production facility economically and efficiently.  Specifically locally installed and centralised environmentally friendly technologies avoid or minimize emissions.

These large-scale production lines for the manufacture of vitamins are maintained, repaired and modernized on an annual basis to meet current demand and achieve a high yield.
Expansion of a pharmaceutical facility

The production process of the substance was overhauled and a second production line is being implemented on top of the first three.  Afterwards the production process will be integrated into the existing processes. To do this, unnecessary parts of the system must be dismantled, new ones introduced, and the system installed and put into operation. The ongoing production on the first production line severely restricts the work.

 

Monoclonal antibody cell culture plant Basel Switzerland

Construction of a biotechnological pharmaceutical production facility for the production of monoclonal antibodies for the treatment of cancer. 

Biofermentation facility Singapore

Construction of a phramaceutical facility for the production of medicine in Singapore. 

Over multiple planning stages the final layout for this investment project for a site for biotechnological production lines was developed and realised.
Insulin facility expansion Frankfurt am Main

The project expands the manufacturing of an insulin product to two production lines with all the necessary plant technology upgrades.  To do this the building must be expanded, the facility assembled and connected to the existing one and qualified. Because production line 1 must continue producing, the work must be sealed off from the clean rooms so as not to endanger production.  The project includes two shut downs in which connections and commissioning have to be implemented under high time pressure.

Construction of a production facility for flu vaccination

The pharmaceutical giant GlaxoSmithKline (GSK) isn’t shying away from the much-maligned pharmaceutical location of Germany: for more than 90m euros the British company enlarged its production facility for flu vaccinations in Dresden. By the 2008/2009 flu season annual production of the vaccine had been doubled.

Biotechnology facility Penzberg

The new laboratory and office complex is the biggest building at the Penzberg site and accommodates six pharmaceutical and two diagnostics departments.  Additionally it contains Bavaria’s largest biotechnology training centre. It also houses medical services, the health centre, storage areas and the cafeteria.

Construction of biotechnical pharmaceutical facility with logicstics unit 

Novartis AG is investing in its Stein site in the construction of a new solids launch facility, a production facility for solid medicines. The mulit-level construction ist 160 metres long and 80 metres wide. In the future on a total area of approx. 60,000m2, it will house production and quality control as well as administrative functions.

 

Clinical sample production area Darmstadt

The project involved the production of a new clinical sample production area. To this end, a complete floor (1700m2 GFA) will be expanded in an existing building and the current old plant closed.

In the clinical sample production area there is no clearly defined product portfolio, therefore used process technologies and stages can vary. The focusof the facility is on the provision of the widest possible range of production technologies, not maximum productivity.

In the new clinical sample production area highly potent substances (OEB 4/5, MEL 4) are handled, the GMP standard improved and the employee safety brought up to the latest technical standards.

 

Verification of packaging features Switzerland

Implementation and management of safety features on pharmaceutical packaging.

 

Online Coding France

Implementation of a system for online coding, serialisation, product tracking, feature verification and OPN – Online Printer Novartis.

Track & Trace Pharma Switzerland

Project for the implementation and management of safety features on pharmaceutical packaging.  Global roll out of the features on all packaging production sites worldwide. E.g. for the U.S. market 45 lines (incl. 23 contractor lines) at 15 sites in 6 countries were modified.

Global product lifecycle management system

The increasing demand for the traceability of pharmaceuticals from manufacturing to the consumer require the construction of complex tracking tools via packaging labels and underlying data that are available to users worldwide. In the project created for this purpose the regulations required on the basis of each country’s legislation are implemented and incorporated into the global structure of the pharmaceutical company.  In a change process all affected production areas and departments are integrated and trained in this process.